Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability of BI 409306 in Healthy Subjects
NCT03505151Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of osoresnontrine in schizophrenia, sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve Extrapolated to Infinity and Maximum Measured Concentration. Started Apr 2018; status: completed.
02
Drugs
osoresnontrine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03505151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505151.